CA
NZ
UK
AU
IND
US
…
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -54.17M | 124.16M | -81.04M | -60.46M | -51.98M |
| Net income | -51.41M | 122.83M | -80.73M | -59.26M | -51.98M |
| Selling general administrative | 32.43M | 37.23M | 30.63M | 19.25M | 19.14M |
| Gross profit | 1.50M | 208.38M | 12.62M | - | 0.00M |
| Reconciled depreciation | 1.38M | 0.24M | 0.31M | 0.26M | 0.14M |
| Ebit | -56.93M | 124.21M | -81.74M | -61.66M | -53.07M |
| Ebitda | -55.55M | 124.45M | -81.43M | -61.41M | -52.93M |
| Depreciation and amortization | 1.38M | 0.24M | 0.31M | 0.26M | 0.14M |
| Non operating income net other | 1.38M | - | - | 0.95M | 0.95M |
| Operating income | -55.55M | 124.21M | -81.43M | -61.41M | -52.93M |
| Other operating expenses | 57.05M | 84.17M | 94.05M | 61.41M | 52.93M |
| Interest expense | 2.76M | 0.05M | 0.00M | 0.00M | 0.00M |
| Tax provision | 0.00M | 1.33M | - | - | - |
| Interest income | - | - | - | 0.95M | 0.95M |
| Net interest income | - | - | - | 0.95M | 0.95M |
| Income tax expense | -2.76M | 1.33M | -0.31M | -1.20M | 0.95M |
| Total revenue | 1.50M | 208.38M | 12.62M | 0.00M | 0.00M |
| Total operating expenses | 57.05M | 84.17M | 94.05M | 61.41M | 52.93M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | 1.38M | -0.05M | 0.40M | 0.95M | 0.95M |
| Net income from continuing ops | -54.17M | 122.83M | -81.04M | -60.46M | -51.98M |
| Net income applicable to common shares | -54.17M | 119.84M | -81.04M | -60.46M | -51.98M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 144.03M | 155.27M | 194.54M | 75.93M | 80.84M |
| Intangible assets | 0.18M | - | - | - | 0.47M |
| Other current assets | 3.76M | 2.38M | 2.68M | 2.67M | 1.94M |
| Total liab | 56.23M | 22.99M | 14.80M | 32.29M | 10.82M |
| Total stockholder equity | 87.80M | 132.27M | 179.75M | 43.63M | 70.02M |
| Deferred long term liab | - | - | - | 10.17M | - |
| Other current liab | 6.53M | 4.50M | 7.67M | 14.40M | 7.28M |
| Common stock | 0.07M | 0.07M | 0.07M | 0.07M | 0.05M |
| Capital stock | 0.07M | 0.07M | 0.07M | 0.07M | 0.05M |
| Retained earnings | -277.87M | -225.53M | -171.36M | -294.19M | -213.16M |
| Other liab | - | - | - | 10.23M | 0.29M |
| Other assets | 0.00M | 1.93M | 2.03M | -0.00M | 0.49M |
| Cash | 27.04M | 129.00M | 187.80M | 72.03M | 41.90M |
| Total current liabilities | 11.47M | 6.99M | 14.80M | 22.06M | 10.53M |
| Current deferred revenue | - | - | - | 2.21M | - |
| Net debt | 18.96M | -112.47M | -187.80M | -72.03M | -41.90M |
| Short term debt | 1.25M | 0.53M | - | - | - |
| Short long term debt total | 46.00M | 16.54M | - | - | - |
| Other stockholder equity | 365.59M | 357.77M | 351.03M | 337.76M | 283.12M |
| Property plant equipment | - | 1.15M | 0.24M | 0.14M | 0.07M |
| Total current assets | 109.60M | 131.38M | 190.48M | 74.84M | 79.81M |
| Long term investments | 17.63M | 5.62M | 1.63M | - | - |
| Net tangible assets | - | 132.27M | 179.75M | 43.31M | 69.56M |
| Short term investments | 78.79M | 84.13M | - | 0.00M | 34.84M |
| Net receivables | - | 0.26M | - | 0.14M | 1.13M |
| Accounts payable | 3.70M | 1.95M | 7.13M | 5.45M | 3.26M |
| Accumulated other comprehensive income | 0.00M | -0.04M | - | - | 0.00M |
| Common stock total equity | - | 0.07M | 0.07M | 0.07M | 0.05M |
| Preferred stock total equity | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings total equity | - | -225.53M | -171.36M | -294.19M | -213.16M |
| Non currrent assets other | 0.03M | 1.97M | 1.93M | 0.63M | 0.50M |
| Non current assets total | 34.43M | 23.89M | 4.07M | 1.08M | 1.03M |
| Capital lease obligations | 16.00M | 16.54M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -85.46M | -1.63M | 35.04M | -29.80M | -5.01M |
| Change to liabilities | -8.34M | -17.47M | 14.72M | 1.82M | 2.74M |
| Total cashflows from investing activities | -87.88M | -1.82M | 34.65M | -30.04M | -5.36M |
| Total cash from financing activities | 0.18M | 0.90M | 47.07M | 86.54M | 0.29M |
| Change to operating activities | -3.06M | -6.13M | 7.10M | 4.59M | -2.44M |
| Net income | -54.17M | 122.83M | -81.04M | -60.46M | -51.98M |
| Change in cash | -142.93M | 117.69M | 30.14M | 5.41M | -50.64M |
| Begin period cash flow | 189.73M | 72.03M | 41.90M | 36.49M | 87.13M |
| End period cash flow | 46.80M | 189.73M | 72.03M | 41.90M | 36.49M |
| Total cash from operating activities | -55.23M | 118.61M | -51.58M | -51.09M | -45.56M |
| Issuance of capital stock | - | 0.00M | 46.73M | 86.41M | 0.00M |
| Depreciation | 1.38M | 0.24M | 0.31M | 0.26M | 0.14M |
| Other cashflows from investing activities | -1.19M | -0.01M | -0.26M | -0.19M | -5.01M |
| Change to account receivables | - | - | 0.99M | - | - |
| Sale purchase of stock | 0.18M | 0.90M | 47.07M | 64.25M | 0.29M |
| Other cashflows from financing activities | -180.48M | 0.90M | 0.34M | 0.13M | 0.29M |
| Change to netincome | 6.56M | 5.05M | 7.33M | 5.21M | 7.07M |
| Capital expenditures | 1.42M | 0.19M | 0.39M | 0.24M | 0.35M |
| Change receivables | - | -0.14M | 0.99M | -0.53M | - |
| Cash flows other operating | 0.21M | 6.89M | -1.06M | 2.62M | -3.53M |
| Cash and cash equivalents changes | -142.93M | 117.69M | 30.14M | 5.41M | -50.64M |
| Change in working capital | -8.23M | -16.81M | 21.82M | 3.94M | -0.79M |
| Stock based compensation | 6.56M | 5.05M | 7.53M | 5.21M | 7.06M |
| Other non cash items | -0.76M | 7.30M | -0.20M | -0.03M | -0.00M |
| Free cash flow | -56.65M | 118.42M | -51.97M | -51.33M | -45.91M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics Inc |
0.03 0.88% |
2.88 | - | 1.79 | 577.67 | 2.58 | 349.23 | -2.37 |
| NVO Novo Nordisk A/S |
1.09 2.72% |
41.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.78 0.69% |
550.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
15.61 1.73% |
919.96 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir | Pres, CEO & Chairman | 1953 |
| Mr. Jeffrey A. Rona | Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer | 1968 |
| Mr. Thomas Michael Perone J.D., M.B.A. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. | 1965 |
| Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D. | Founder & Member of Scientific Advisory Board | 1957 |
| Mr. Jason Tardio M.B.A. | Chief Operating Officer | 1977 |
| Ms. Lora Pike | Sr. Director of Investor Relations & PR | NA |
| Mr. Simon D. Kelner | Sr. VP & Chief HR Officer | 1973 |
| Dr. Dirk Haasner | Sr. VP of Global Manufacturing & CMC QA | 1965 |
| Ms. Suzanne K. Wakamoto SHRM-SCP, SPHR | Sr. VP of Culture & Facilities | NA |
| Dr. Claude Nicaise M.D. | Head of R&D | 1953 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.88%
Communication Services
+1.14%
Consumer Cyclical
+1.04%
Consumer Defensive
+0.57%
Energy
+0.50%
Financial Services
+0.81%
Financials
+0.24%
Healthcare
+1.35%
Industrials
+1.54%
Real Estate
+0.24%
Technology
+2.32%
Utilities
+0.48%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
-4.40%
Please wait processing your request...